Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality.


Journal Article

An increased circulating level of fibroblast growth factor 23 (FGF23) is an independent risk factor for mortality, cardiovascular disease, and progression of chronic kidney disease (CKD), but its role in transplant allograft and patient survival is unknown. We tested the hypothesis that increased FGF23 is an independent risk factor for all-cause mortality and allograft loss in a prospective cohort of 984 stable kidney transplant recipients. At enrollment, estimated GFR (eGFR) was 51 ± 21 ml/min per 1.73 m(2) and median C-terminal FGF23 was 28 RU/ml (interquartile range, 20 to 43 RU/ml). Higher FGF23 levels independently associated with increased risk of the composite outcome of all-cause mortality and allograft loss (full model hazard ratio: 1.46 per SD increase in logFGF23, 95% confidence interval: 1.28 to 1.68, P<0.001). The results were similar for each component of the composite outcome and in all sensitivity analyses, including prespecified analyses of patients with baseline eGFR of 30 to 90 ml/min per 1.73 m(2). In contrast, other measures of phosphorus metabolism, including serum phosphate and parathyroid hormone (PTH) levels, did not consistently associate with outcomes. We conclude that a high (or elevated) FGF23 is an independent risk factor for death and allograft loss in kidney transplant recipients.

Full Text

Duke Authors

Cited Authors

  • Wolf, M; Molnar, MZ; Amaral, AP; Czira, ME; Rudas, A; Ujszaszi, A; Kiss, I; Rosivall, L; Kosa, J; Lakatos, P; Kovesdy, CP; Mucsi, I

Published Date

  • May 2011

Published In

Volume / Issue

  • 22 / 5

Start / End Page

  • 956 - 966

PubMed ID

  • 21436289

Pubmed Central ID

  • 21436289

Electronic International Standard Serial Number (EISSN)

  • 1533-3450

Digital Object Identifier (DOI)

  • 10.1681/ASN.2010080894


  • eng

Conference Location

  • United States